COYA 302
phase 2drug program · high · Wed Oct 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate a dual immunomodulatory Treg-enhancing therapy for adults with amyotrophic lateral sclerosis, aiming to enhance anti-inflammatory regulatory T cell function and suppress inflammation from activated monocytes and macrophages.
Proprietary biologic combination therapy comprised of low-dose interleukin-2 and DRL_AB, a biosimilar candidate for abatacept; evaluated in the randomized ALSTARS Phase 2 trial against placebo with ALSFRS-R, neurofilament, respiratory, neurological, biomarker, and safety assessments.
ALSTARS Phase 2 trial listed as enrolling across 20-25 sites in the US and Canada, with a 24-week double-blind period and 24-week blinded active extension.
Website cites proof-of-concept data in ALS, but the supplied material does not provide detailed numerical results.
COYA 101
undiscloseddrug program · medium
Pipeline-listed program within Coya Therapeutics' broader strategy to enhance regulatory T cell function for neurodegenerative, autoimmune, or metabolic diseases.
Specific intervention details are not provided in the supplied material; the company describes its broader approach as Treg-enhancing biologics, Treg-derived exosomes, and Treg cell therapy.
Listed on the company pipeline.
COYA 201
undiscloseddrug program · medium
Pipeline-listed program within Coya Therapeutics' broader strategy to enhance regulatory T cell function for neurodegenerative, autoimmune, or metabolic diseases.
Specific intervention details are not provided in the supplied material; the company describes its broader approach as Treg-enhancing biologics, Treg-derived exosomes, and Treg cell therapy.
Listed on the company pipeline.
COYA 301
undiscloseddrug program · medium
Pipeline-listed program within Coya Therapeutics' broader strategy to enhance regulatory T cell function for neurodegenerative, autoimmune, or metabolic diseases.
Specific intervention details are not provided in the supplied material; the company describes its broader approach as Treg-enhancing biologics, Treg-derived exosomes, and Treg cell therapy.
Listed on the company pipeline.
Treg Enhancement Platform
exploratoryplatform · high
Develop multi-modality therapies that enhance regulatory T cell function for neurodegenerative, autoimmune, and metabolic diseases.
Platform approach using Treg-enhancing biologics, Treg-derived exosomes, and Treg cell therapy; supported by research literature on regulatory T cells in neurodegenerative and nervous system pathologies.
Company describes a proprietary multi-modality Treg therapy platform and lists multiple pipeline programs derived from this approach.
Supplied material states proof-of-concept data in ALS and Alzheimer's, but does not provide detailed study results.
